Archived explainer. For the current picture see today's TLX page.
Why Is TELIX PHARMACEUTICAL ADR (TLX) Stock Up Today?
By the Top Tier Newswire AI Desk · September 14, 2026 at 10:44 AM ET · reviewed against 4 wire stories
TELIX PHARMACEUTICAL ADR (TLX) is up +7.00% in the latest session. Our newswire has captured 4 stories on TLX across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 70/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Telix Pharmaceuticals ADR (TLX) rose 7.00% to $12.08 in morning trading after the U.S. Food and Drug Administration approved its brain cancer imaging drug Pixclara. The drug is the first FET-PET imaging agent approved for glioma, a type of brain cancer, and is expected to help physicians distinguish between tumor recurrence and treatment-related changes. The approval represents a major milestone for the company and has driven significant investor interest.
What Happened
The FDA’s approval of Pixclara marks a significant regulatory win for Telix. The drug is designed to address a critical unmet need in the treatment of glioma, where accurate imaging is essential for effective care. The approval was announced in the past 36 hours and has been widely covered in financial media. The stock opened at $12.03, a 6.6% increase from the previous day’s close, and reached a session high of $12.32 shortly after the market opened. The stock has traded as low as $11.67 during the session but has largely remained in positive territory.
What The Data Shows
Telix has a market capitalization of $3.8 billion and a P/E ratio of 118.4, reflecting its high valuation relative to earnings. The stock opened at a price that was 1.6 times the 3-month average daily volume, indicating strong initial demand. Over the past eight sessions, the stock has gained 5.7%, rising from $11.45 to $12.10. The stock is currently trading within its 52-week range of $6.28 to $12.48. Social media chatter has been minimal, with only one post in the past 24 hours and one in the past week.
What To Watch
Investors should monitor the company’s next steps in commercializing Pixclara and any additional regulatory or clinical developments. The stock is also under coverage from analysts, including HC Wainwright & Co., which reiterated a Buy rating and a $20 price target.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
TLX · today's session (5-min) · +4.34% vs prior close · updated 4:10 PM ETAI sentiment, last 36h · averaged over 4 stories · 70/100 bullish
The headlines behind the move
Story flow · 4 stories on the wire, last 36h · hover or tap a dot for the headline
9h agoBusiness InsiderBULLISH 73Product/PR
FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related...
17h agoInvesting.com MarketsNEUTRAL 50General
Why is Telix Pharmaceuticals stock surging today?
Why is Telix Pharmaceuticals stock surging today?
17h agoInvesting.com MarketsBULLISH 82Product/PR
Telix Pharma wins FDA approval for brain cancer treatment, shares surge
Telix Pharma wins FDA approval for brain cancer treatment, shares surge
19h agoSeeking AlphaBULLISH 73Product/PR
FDA approves Telix brain cancer imaging drug Pixclara
FDA approves Telix Pharmaceuticals’ Pixclara (FET-PET) for glioma imaging, helping distinguish recurrence from treatment effects.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →